- Investigator
- Gurjit S Kaeley
- Ages
- 18 Years - 75 Years
- Sexes
- All
Clinical trials
-
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) -
SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE - Investigator
- Gurjit S Kaeley
- Ages
- 18 Years - 63 Years
- Sexes
- All